<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.ajmc.com/view/fda-adds-head-to-head-maple-hcm-data-to-aficamten-label-in-ohcm</loc>
      <lastmod>2026-11-17T20:10:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T20:10:00Z</news:publication_date>
        <news:title><![CDATA[FDA Adds Head-to-Head MAPLE-HCM Data to Aficamten Label in oHCM]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/in-psoriasis-il-23-inhibitors-tied-to-lower-psa-risk-than-jaks</loc>
      <lastmod>2026-11-17T19:18:31.281Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T19:18:31.281Z</news:publication_date>
        <news:title><![CDATA[In Psoriasis, IL-23 Inhibitors Tied to Lower PsA Risk Than JAKs]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/tirzepatide-lowers-bmi-by-185-in-adolescents-with-obesity</loc>
      <lastmod>2026-11-17T17:50:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T17:50:00Z</news:publication_date>
        <news:title><![CDATA[Tirzepatide Lowers BMI by 18.5% in Adolescents With Obesity]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/urban-hospital-care-linked-to-better-hfref-outcomes-for-rural-patients</loc>
      <lastmod>2026-11-17T16:23:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T16:23:00Z</news:publication_date>
        <news:title><![CDATA[Urban Hospital Care Linked to Better HFrEF Outcomes for Rural Patients]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/choosing-among-emerging-systemic-agents-for-vitiligo</loc>
      <lastmod>2026-11-17T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Choosing Among Emerging Systemic Agents for Vitiligo]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/individualizing-third-line-treatment-in-mcrc</loc>
      <lastmod>2026-11-17T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Individualizing Third-Line Treatment in mCRC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/selecting-asthma-patients-for-6-month-il-5-dosing-fit-and-safety</loc>
      <lastmod>2026-11-17T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Selecting Asthma Patients for 6-Month IL-5 Dosing: Fit and Safety]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/braf-v600e-mcrc-targeted-therapy-and-rechallenge-strategies</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[BRAF V600E mCRC: Targeted Therapy and Rechallenge Strategies]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/preparing-for-systemic-treatment-options-meeting-the-moment-in-vitiligo</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Preparing for Systemic Treatment Options: Meeting the Moment in Vitiligo]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/glp-1s-alone-won-t-solve-obesity-jama-summit-report-says</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/ultra-long-acting-il-5-inhibition-a-paradigm-shift-in-asthma-care</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Ultra-Long-Acting IL-5 Inhibition: A Paradigm Shift in Asthma Care]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/fda-approves-dexmedetomidine-sublingual-film-as-at-home-agitation-therapy</loc>
      <lastmod>2026-11-16T21:22:52.702Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T21:22:52.702Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/andrew-kuykendall-md-says-rusfertide-could-individualize-pv-care</loc>
      <lastmod>2026-11-16T21:02:39.711Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T21:02:39.711Z</news:publication_date>
        <news:title><![CDATA[Andrew Kuykendall, MD, Says Rusfertide Could Individualize PV Care]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/inebilizumab-works-early-or-late-in-gmg-richard-j-nowak-md-ms</loc>
      <lastmod>2026-11-16T20:10:51.488Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T20:10:51.488Z</news:publication_date>
        <news:title><![CDATA[Inebilizumab Works Early or Late in gMG: Richard J. Nowak, MD, MS]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/shorter-us-residence-linked-to-greater-crc-screening-nonadherence</loc>
      <lastmod>2026-11-16T20:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T20:00:00Z</news:publication_date>
        <news:title><![CDATA[Shorter US Residence Linked to Greater CRC Screening Nonadherence]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/new-hdv-therapies-could-spur-more-testing-nancy-reau-md-faasld</loc>
      <lastmod>2026-11-16T19:08:09.039Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T19:08:09.039Z</news:publication_date>
        <news:title><![CDATA[New HDV Therapies Could Spur More Testing: Nancy Reau, MD, FAASLD]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/ribupatide-yields-up-to-17-7-weight-loss-in-phase-3-gemini-1-trial</loc>
      <lastmod>2026-11-16T18:12:05.460Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T18:12:05.460Z</news:publication_date>
        <news:title><![CDATA[Ribupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 Trial]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/madhav-seshadri-md-maps-unmet-needs-in-aggressive-lymphomas</loc>
      <lastmod>2026-11-16T18:11:13.929Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T18:11:13.929Z</news:publication_date>
        <news:title><![CDATA[Madhav Seshadri, MD, Maps Unmet Needs in Aggressive Lymphomas]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/eclipse-1-shows-rapid-hdv-suppression-nancy-reau-md</loc>
      <lastmod>2026-11-16T17:54:26.825Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T17:54:26.825Z</news:publication_date>
        <news:title><![CDATA[ECLIPSE 1 Shows Rapid HDV Suppression: Nancy Reau, MD]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/menopause-benefit-design-should-prioritize-access-total-cost-of-care</loc>
      <lastmod>2026-11-16T16:44:56.789Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:44:56.789Z</news:publication_date>
        <news:title><![CDATA[Menopause Benefit Design Should Prioritize Access, Total Cost of Care]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/fda-approves-weekly-gefurulimab-for-generalized-myasthenia-gravis</loc>
      <lastmod>2026-11-16T16:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:30:00Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Weekly Gefurulimab for Generalized Myasthenia Gravis]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/alopecia-areata-might-be-tied-to-higher-long-term-glaucoma-risk</loc>
      <lastmod>2026-11-16T15:39:16.070Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T15:39:16.070Z</news:publication_date>
        <news:title><![CDATA[Alopecia Areata Might Be Tied to Higher Long-Term Glaucoma Risk]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/b3-agonists-no-dementia-advantage-over-anticholinergics-in-oab</loc>
      <lastmod>2026-11-16T15:30:35.530Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T15:30:35.530Z</news:publication_date>
        <news:title><![CDATA[β3 Agonists Show No Dementia Advantage Over Anticholinergics in OAB]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/choosing-an-hs-biologic-comorbidities-access-and-adherence-barriers</loc>
      <lastmod>2026-11-16T15:21:22.050Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T15:21:22.050Z</news:publication_date>
        <news:title><![CDATA[Choosing an HS Biologic: Comorbidities, Access, and Adherence Barriers]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/setting-hs-treatment-goals-and-building-a-multimodal-regimen</loc>
      <lastmod>2026-11-16T15:14:44.759Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T15:14:44.759Z</news:publication_date>
        <news:title><![CDATA[Setting HS Treatment Goals and Building a Multimodal Regimen]]></news:title>
      </news:news>
	</url></urlset>